Levosimendan In Ambulatory Heart Failure Patients

PHASE4

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The level of recruitment, 62 participants enrolled, does not allow for achieving the protocol-defined target of 350 participants by the end of the recruitment period.

Conditions

Heart Failure New York Heart Association Class III
Heart Failure New York Heart Association Class IV
Heart Failure, Systolic
Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: Levosimendan
OTHER: Placebo

Sponsor

Medical University of Bialystok

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]